- Home
- TOPS vs GLTO Comparison
TOPS vs GLTO Comparison
Compare TOPS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- GLTO
- Stock Information
- Founded
- TOPS 2000
- GLTO 2011
- Country
- TOPS Greece
- GLTO Denmark
- Employees
- TOPS N/A
- GLTO N/A
- Industry
- TOPS Marine Transportation
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- GLTO Health Care
- Exchange
- TOPS Nasdaq
- GLTO Nasdaq
- Market Cap
- TOPS 27.0M
- GLTO 23.7M
- IPO Year
- TOPS 2004
- GLTO 2020
- Fundamental
- Price
- TOPS $5.91
- GLTO $7.47
- Analyst Decision
- TOPS
- GLTO
- Analyst Count
- TOPS 0
- GLTO 0
- Target Price
- TOPS N/A
- GLTO N/A
- AVG Volume (30 Days)
- TOPS 8.9K
- GLTO 4.7M
- Earning Date
- TOPS 11-14-2025
- GLTO 11-04-2025
- Dividend Yield
- TOPS N/A
- GLTO N/A
- EPS Growth
- TOPS N/A
- GLTO N/A
- EPS
- TOPS 2.30
- GLTO N/A
- Revenue
- TOPS $87,872,000.00
- GLTO N/A
- Revenue This Year
- TOPS $9.90
- GLTO N/A
- Revenue Next Year
- TOPS N/A
- GLTO N/A
- P/E Ratio
- TOPS $2.66
- GLTO N/A
- Revenue Growth
- TOPS 4.77
- GLTO N/A
- 52 Week Low
- TOPS $5.00
- GLTO $2.01
- 52 Week High
- TOPS $11.47
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- TOPS 58.38
- GLTO 48.62
- Support Level
- TOPS $5.92
- GLTO $7.02
- Resistance Level
- TOPS $6.21
- GLTO $8.61
- Average True Range (ATR)
- TOPS 0.29
- GLTO 1.08
- MACD
- TOPS 0.02
- GLTO -0.61
- Stochastic Oscillator
- TOPS 82.84
- GLTO 5.82
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.